Q4 2021 Brooks Automation Inc Earnings Call
Thank you for standing by your conference call will begin momentarily. If you did wish to register a question during the presentation. It's the one followed by the four on your keypad.
[music].
Greetings and welcome to the Brooks automation Q4, 2021 financial results.
During the presentation, all participants will be in a listen only mode. Afterwards, we will conduct a question and answer session.
At that time, if you have a question. Please press the one followed by the four on your telephone.
If at any time during the conference you need to reach an operator, Please press star Zero and as a reminder, this conference is being recorded Wednesday November 10th 2021, I will now turn the conference over to Sarah Silverman Director of Investor Relations. Please go ahead.
Thank you operator, and good afternoon to everyone on the line today, we would like to welcome you to our earnings conference call for the fourth quarter of fiscal year, 2020 one.
Our fourth quarter earnings press release was issued after the close of the market today and is available on our Investor Relations website located at Brooks that Investor owned Dot Com. In addition to the supplementary Powerpoint slides that will be used during the prepared remarks today.
Please note that due to the divestiture announced on September 20th 'twenty 'twenty. One the result of the semiconductor automation business are treated as discontinued operations.
I would like to remind everyone that during the course of the call we will be making a number of forward looking statements within the meaning of the private litigation Securities Act of 1995.
There are many factors that may cause actual financial results or other events to differ from those identified in such forward looking statements.
I'd refer you to the section of our earnings release titled Safe Harbor statement, the Safe Harbor slide on the aforementioned Powerpoint presentation on our website and our various filings with the SEC, including our annual reports on Form 10-K, and our quarterly reports on Form 10-Q.
We make no obligation to update these statements should future financial data or events occur that differ from the forward looking statements presented today.
We may refer to a number of non-GAAP financial measures, which are used in addition to and in conjunction with results presented in accordance with GAAP.
We believe the non-GAAP measures provide an additional way of viewing aspects of our operations and performance, but we considered with GAAP financial results and a reconciliation of GAAP measures. They provide an even more complete understanding of the brokerage business.
Non-GAAP measures should not be relied upon to the exclusion of the GAAP measures themselves.
On the call with me today is our president and Chief Executive Officer, Steve Schwartz.
And our executive Vice President and Chief Financial Officer Lindon Robertson.
We will open the call with remarks from Steve on highlights of the fourth quarter, then lindon will provide a more detailed look into our financial results and our outlook for the first fiscal quarter of 2022.
We will then take your questions at the end of the prepared remarks with that I'd like to turn the call over to our CEO Steve Schwartz.
Thank you Sarah good afternoon, everyone and thank you for joining us today.
We had another productive quarter setting ourselves up for what will be the next exciting phase of growth and continued market leadership.
With a considerably different configuration compared with the Brooks automation, you've come to know over the past decade.
In the quarter, we announced the sale of our semiconductor automation business to Thomas H Lee partners and the launch of a sensor life Sciences, our newly branded life Sciences business.
Both of these initiatives are key to delivering more shareholder value.
The result of these actions will significantly change the makeup of the company.
We will continue to actively manage both businesses until the sale is complete.
Financial reporting changes are immediate and the semiconductor automation business is now classified as discontinued operations.
Beginning with today's Q4 results, we will provide limited commentary about the semiconductor automation business, but enough to highlight another quarter of strong performance and to reinforce that the outlook remains solid.
Most of what Lindon and I will convey relates to exempt the life Sciences.
So before we move to the life Sciences view only I do want to reflect on the performance of the company in aggregate as we closed our fiscal year 2021 at the end of September.
Total revenue for the quarter for the full company was $342 million.
Up 39% year over year and.
Revenue for the full year was $1 2 billion, an increase of 33% from fiscal 2020.
In the mix for Q4 semiconductor automation revenue was $205 million up 49% year over year.
Suffice it to say the semiconductor automation business remains robust and the outlook for 2022 is for another very strong year.
Not be giving the granular performance data for the semiconductor automation business. However, I will mention that we will still continue to operate the business until the transaction closes.
As such we continue to invest to support growth and to be certain that when the transfer. It takes place the semiconductor automation business did not skip a beat.
Linda will provide a bit more color as to the implications of this arrangement on our near term financials as we continue to operate both businesses pre close.
From this point in my remarks, I'll be speaking only about the life Sciences business, which on the 28th of September we launched as a sensor life Sciences, the name and brand of our New company.
And last week on the first of November we began conducting business with our customers as the center.
We're excited to launch with a new identity that unites us around our unique portfolio of offerings.
Our rollout has been met with enthusiasm from our employees and customers alike.
We're eager to where a new brand deliver on our promise and engage each other with the singular purpose.
To enable breakthrough therapies to be brought to market faster.
We do believe that what we do truly makes a difference in the world.
We will have much more to say about us into life Sciences that are virtual investor and analyst day next week on November 16th.
We hope that youll be able to attend.
So now I am pleased to report on an outstanding year for them to life Sciences, one marked by significant achievements and punctuated by the fact that it's about to stand on its own as a unique pure play life Sciences company.
Revenue for the quarter was $137 million up 27% from Q4 last year and we finished the full fiscal year with revenue totaling $514 million up 32% from 2020.
Our strong growth momentum continued across services and products with both segments delivering record revenues.
Customer capture remained robust as once again, we added more than 300, new customer accounts in the quarter.
As a center our focus now is to unify and expand the value proposition that we bring to our customers throughout the critical sample workflow.
All discovery and therapeutic development is based on biological samples whether from humans animals plants were synthesized and laboratories.
Each of these samples requires care throughout its lifecycle from proper sourcing formatting and temperature controlled transportation.
Storage and retrieval genomic analysis, and annotation and ultimately proper archiving for subsequent future use.
Is this sample management chain of custody has become more critical it has simultaneously become more complex both because of the sheer number of samples that customers must manage but also the executive management of the conditions under which the samples must be cared for.
Add to that the myriad potential analytical capabilities that are possible plus the voluminous complex data annotation requirements that must securely be attached each sample and you have a compounding challenge where any step in the workflow the potentially compromise the integrity of results <unk>. The security of particular irreplaceable collections of SAP.
Yeah.
Enter agenda.
It is exactly to meet this challenge that we exist to.
To assist our customers with the precise management of their precious samples and additional value added scientific data extraction from these assets that allowed them to derive maximum value from these symptoms.
With each passing day and with each incremental product and service offerings that our customers ask us to deliver we are proving the value of our unique portfolio that truly enables them to bring breakthrough treatments to market faster.
In a year end quarter full of highlights I gave color to a few of the trends that are shaping our business.
Our services business reported revenue of $84 million for the quarter with 20% growth year over year.
Revenue for the full year was $314 million with 21% growth and strong contributions from each of the major sub segment next generation sequencing Sanger sequencing and synthesis.
Notably we saw the largest expansion from our NGL business driven by demand for our new RNA sequencing service innovation and enabled by capacity additions we've made to stay in front of these opportunities.
The sample and repository solutions business also maintained strong growth with steady sample inflow from our two most recent large pharma customer wins.
An expansion of our onsite sample management services business and.
In the quarter. We also celebrated the opening of our Cleveland clinic by a repository, which is an important proof point for our flexible sample management model. Additionally.
Additionally, the opportunity pipeline continues to grow and we're confident in another good growth year for the Srs business in fiscal year 2022.
The products business reported revenue of $53 million for the quarter was 38% growth year over year.
Revenue for the full year was $200 million with 54% growth.
This was a record quarter for the products business led by another sequential increase in consumables, where demand remains robust partially because of COVID-19 testing, but sustaining because of share gains we've made over the past 18 months.
We are particularly pleased by the growth momentum from our cryogenics products.
We had a record quarter for the bio store cryo systems with continued strong shipments into cell and gene therapy applications, where we once again added several new customers. In addition to shipments for the management of cell lines in various stages of vaccine development.
Furthermore, we are significantly expanding our customer base as a result of a wave of momentum moving to automated cryogenic sample storage system.
Across all of the event the offerings, we have steady growth from existing customers, but we continue to see acceleration from the rapid adoption of our enabling cell and gene therapy products and services, which are beginning to drive persistent revenue expansion quarter over quarter.
In Q4 cell and gene therapy applications still represented less than 10% of our revenue, but the contribution was up 33% year over year.
We anticipate continued growth from cell and gene therapy as our offerings solve some of the most immediate challenges facing scientists today.
Furthermore, we believe that it's the way that we combine our cell and gene therapy capabilities into solutions that makes our capabilities, even more valuable to customers.
As we've said many times we are still in the earliest stages of this opportunity that is being fueled by a period of biological science discovery that sort of pace unprecedented in human history.
We are uniquely and deliberately positioned to be a critical enabler across all segments of these endeavors.
We're about to be in a very different position from when our semiconductor automation business was delivering a significant portion of our profitability.
As a standalone life Sciences company, we plan to maintain a strong growth trajectory. So that we can once again accelerate profit by leveraging our infrastructure.
We're confident that the course, we've chartered will allow us to satisfy the subjective.
Secondly, upon the closing of the sale of the semiconductor automation business will have more than $2 5 billion of cash on our balance sheet with which we will further build out our capability along the sample value chain.
As always our first priority for investment is for organic growth by expansion of existing capabilities and internal investments and innovation.
However, the substantial cash position will give us opportunities to bring more transformative capabilities into our portfolio faster.
We have an active pipeline of potential opportunities and we're a company with a proven ability to bring acquisitions successfully into our fold.
We have more exciting growth days ahead.
We're proud of our entire global team the Brooks semiconductor automation business is destined for more success under THL, who will provide them the support deserving of an innovative pure play automation company.
Similarly, as events of life Sciences, we're positioned with a powerful value, adding portfolio of products and services that enables the life sciences industry. We.
We have a hugely talented global team dedicated to delivering on our promise to enable our customers' success.
And our balance sheet will be a unique strategic advantage as we work to capture this opportunity.
As always we thank you for your interest and support as we work to deliver value to our customers and shareholders.
I'll now turn the call over to Lindon.
Thank you Steve I'll now refer you back to the slide deck available on our website turning to slide three.
As Steve referenced I will be brief with remarks regarding the semi business, but I do want to highlight a few points with semi included.
For clarity of how we performed against expectations, we achieved the high end of our prior guidance range for Q4 under the aggregate view SME.
In that context non-GAAP earnings per share was <unk> 78 up 67% year over year.
Both life Sciences, and semi showed continued topline growth and strong profitability.
Jimmy had another high growth quarter with $205 million of revenue up 49% year over year.
In life Sciences generated revenue of 137 million, reaching the high end of our guidance expectations with growth of 27% year over year.
Due to the pending sale are reporting our results will treat the semiconductor business as discontinued operations and our continued operations will consists exclusively of our life Sciences business.
Total GAAP earnings per share was 29.
And I will break this down on our next page.
In the appendix of this presentation, we have provided more details in the aggregate view of non-GAAP results for direct comparison to historical results. However, the remainder of my remarks will focus on the continuing operations, which consists of the life Science services and life Science products segment and represents the ongoing business.
As mentioned life Sciences finished the year strong with Q4 revenue of $137 million up 27% year over year and up 24% on an organic basis, both products and services business delivered over 20% growth for the quarter and the full year.
Adjusted EBITDA margin was 15, 5% and is net of 250 basis points headwind of overlapping G&A structure that is expected to roll off when the sale closes.
We'll provide more details on this later in my remarks, but perhaps most importantly, we remain on track to achieve 22% adjusted EBITDA margin as we exit fiscal year 2022.
Of course, it was our September 20th announcement of reaching an agreement to sell our semiconductor automation business, which has driven these changes to our reporting.
The agreement was to sell the business for $3 billion in cash.
We expect net proceeds of $2 4 billion from the transaction and expect to have approximately $2 $6 billion in net cash available to deploy for strategic investment in the life Sciences business.
Moving to slide four first let's take a closer look on a GAAP basis, which youll see on the left side of the page.
Revenue was up 6% sequentially and up 27% year over year.
Looking at the bottom line total GAAP earnings per share, including the discontinued operations was a profit of 2009.
Which includes 50 <unk> classified as discontinued operations.
The GAAP earnings per share from continuing operations was a loss of <unk> 30 for the quarter.
The gross margin was stable, while lower operating margin reflects expenses related to separating and standing of the two businesses.
Operating expenses in the quarter include approximately $8 million of corporate expenses related to separating the semi business and $13 million of noncash expense related to the retirement of trade names as we establish the new brands.
Additionally, there is an incremental burden of cost in our overlapping corporate structure, which is actively supporting both businesses until final separation is achieved.
Below the operating income line, we had $16 million of non operating expense related to the release of a tax indemnification asset.
The $16 million charge, that's out to zero at the net income line as we simultaneously eliminated a related $16 million potential tax liability.
Now, let's dive deeper into the non-GAAP P&L on the right side of the page.
We delivered another strong quarter in life Sciences to round out what has been a truly transformational year for the business.
Organic growth was 24% in the quarter.
The Covid related revenue was relatively stable sequentially and predominantly in the consumables business, which had about $11 million.
Life Sciences gross margin saw a slight decline of 30 basis points quarter over quarter, and 80 basis points year over year.
Collecting performance improvements in products offset by modest margin pressure in services on which I will provide additional color later in my segment remarks.
Operating income was down 40 basis points sequentially and up 120 basis points year over year, showing the temporary pressure of increased G&A structure in the quarter, but also demonstrating the strong operating leverage in the business as our revenue continues to grow faster than our operating expense.
Sure.
Let me provide more color around the changes to the reporting of our continuing operations are we foresee transitioning to the transaction closure and on through to the end of fiscal 2022.
As you may recall from prior quarters I have explained that the separation of the two companies would put approximately five points of pressure on the Standalone life Sciences adjusted EBITDA margin.
At the last call. Our Q3 adjusted EBITDA margin was approximately 23% so on a standalone basis, you might expect 18%.
However, as long as we are supporting the discontinued operations, we continue to carry some overlapping G&A and our corporate functions that drive an additional 250 basis points of expense.
This extra cost will be about 300 basis points in Q1, as we will have nearly a full quarter of overlapping structure when.
When we closed the deal and finalize the separation, which is expected in the first half of calendar year 2022, we expect to shed this extra expense and see immediate improvement.
Meanwhile, as we continue to grow across the quarters of 2022, the leverage of our business model will continue to produce enhanced margins and we expect to exit the fourth quarter of fiscal 'twenty two.
Adjusted EBITDA margin of 22%.
With that in mind this quarter, we reported 15 in the 5% adjusted EBITDA margin for life Sciences, 100 basis point improvement quarter over quarter on a continuing operations basis.
Turning now to slide five for results of our continuing operations on a full year basis again, you will see incredibly strong revenue growth of 32%.
Organic growth for the year came in at similar 33% driven by growth in both segments.
Gross margins expanded 360 basis points, driven by margin improvement in both life science products and life Sciences services.
Non-GAAP operating margins as viewed on a continuing operations basis for both periods increased from breakeven in fiscal 2020 to nine 1% in fiscal 2021.
The full year tax rate was 23%, culminating in full year non-GAAP earnings per share of <unk> 48.
Compared to <unk> for fiscal 2020.
Full year adjusted EBITDA margin on a continuing operations basis was 16, 7% up an impressive 950 basis points year over year.
Now please turn to page six for a review of our life Science products segment results.
The products business in total was $53 million up 9% quarter over quarter and up 38% year over year.
The year over year increase was driven by 79% growth in storage systems, and 30% growth in consumables and instruments.
The life Sciences products Q4, gross margin was 47, 9%, a 390 basis point improvement year over year, driven by strong margins in our automated stores business.
Q4 operating margin of 12, 4% expanded 910 basis points over last year, driven by the gross margin improvement and operating leverage in the business.
Adjusted EBITDA shows the same margin expansion and came in at 17%.
Next please turn to page seven for a review of our life Science service segment results.
Services business generated revenue of $84 million, an increase of 20% year over year and 4% on a sequential basis. As a reminder, this business is comprised of our genomic services business and our sample repository solutions offerings.
The genomic services business grew 22% year over year, driven by double digit growth across all service lines.
Paper repository solutions also delivered strong growth driven by storage up 16% year over year and up 25%, excluding the impact of our UC Dr. <unk>.
Sequentially.
Srs revenue for the fourth quarter was up a strong 12%.
If we adjust total service revenue for the impact of our <unk> services growth was 22%.
Services business delivered 58% gross margin April slightly this quarter following higher than average utilization earlier in the year.
This level of gross margin remains within our target range for now and reflects recent investments in the labor force both in hiring for capacity and compensation levels for retention.
This brought the adjusted EBITDA margin of 14, 2%.
We foresee the services business gross margin fluctuating around this level for the near future and providing a return to EBITDA margin expansion with the revenue growth.
Let's turn to slide eight for the summary of cash flow for the quarter.
Our operating cash flow as reported on a consolidated basis, including results from discontinued operations.
We generated operating cash flow of $150 million over the past year, which included cash outflows of $22 million related to the separation costs.
The working capital line reflects prudent investments to support the growth of both businesses throughout the year.
Capital expenditures for this quarter totaled $18 million, including $2 million for semi.
Clubs and eight sample repository solution locations around the world, but we also have building and leasehold improvements and beyond this the line is comprised of software and other assets.
Let's turn to slide 10, now for a guidance on the first fiscal quarter of 2022.
Revenue from continuing operations is expected to be in the range of $130 million to $140 million with the midpoint supporting growth of approximately 15% year over year.
Adjusted EBITDA is expected to be $14 million to $22 million and.
And non-GAAP earnings per share is expected to be four to 12 cents per share.
As I said earlier, we continue to expect the Standalone business to return to around 22% adjusted EBITDA margin by the fourth fiscal quarter of 2022.
For the full year, we expect capital expenditures in support of life sciences to be approximately $60 million to $70 million, including approximately 25 million for the China genomics building site.
We estimate that the non-GAAP tax rate will be in the range of 17% to 21%.
Turning now to slide 11, we will wrap up our prepared remarks.
We are truly one of a kind life Sciences company, we continue to deliver strong profitable growth and as I mentioned, you will see this profit capability, even more clearly once we complete sales semi business.
We have a strong balance sheet for strategic investment, which we expect to grow even stronger with completion of the sale of the semi business expected in the first half of calendar 2022.
We have around $200 million net cash position today with an anticipated balance of approximately $2.6 billion. Upon completion of this sale.
We are excited about the launch of these unto life science business, we will be hosting a virtual investor day Ah next Tuesday November 16, starting at nine am Eastern time, we welcome to investors and analysts to attend virtually as we have a broader group of our management team join in presenting our business capabilities and outlook.
And of course, we will provide a new three year target model, describing our objectives for fiscal year 2024.
A link to the registration page is available in the events section of our Investor Relations website. Please reach out to Sarah Silverman or head of Investor Relations. If you have any questions and we look forward to speaking with you all next week.
This concludes our prepared remarks, I will now turn the call back over to the operator to take your questions.
Thank you so to register a question press. The one followed by the four on your keypad, you'll hear a three tone prompt that acknowledges you request for your question has been answered and you would like to withdraw your registration press. The one followed by the three so again for questions. It's one four.
First question is from David Saxon with need them and that lines open.
Great Good afternoon, and thanks, so much for taking the questions.
I guess my my two questions vs on Srs secondhand Jacque rates for Srs I think you said X the alliance it grew around 25%.
You noted some steady sample and flows and capacity expansion, starting a Cleveland clinic et cetera, just wondering if you could frame, how we should be thinking about.
Sarah S.
In the fiscal first quarter, but also just physical 22.
Hey, David Thank thank slept.
For the third.
The growth has been really nice on the Srs businesses. We've seen two types of activity through to 2021. One is we've highlighted in the past we've picked up to global customers.
Are looking for us.
And we're already engaged to start supporting their global sample collection.
We're really an extension of their infrastructure and activity.
And then secondly, as you've seen in 2021, we've also and.
Engaged in additional vaccine management as well.
So as we go into Q1, our services business does look to be quite stable and expanding and on the Srs. It's.
No exception factor services business.
When we look into Q1 that has the stronger expansion step as we go into the December quarter.
So I think the the strength here continues the momentum does.
And <unk>.
Quite excited phone.
Hey, David This is Steve I'll give you a little bit more certainty and uncertainty around the Srs business. So we talked about two large pharma companies that recently gave us basically all of their samples and with one we have almost all of the North American samples relocated and we're starting this current month in Europe.
To do the similar kind of move to our European Biorepository source faced stage here.
On the one that we most recently one of work consolidating the sample collections from multiple sites. So we have a team actually more than 20 people dispatched out at the site cataloging characterizing the sample collections, but all the while while we do that and then also when we moved the samples to our bio repositories, we have.
Clinical trial activity going along with them simultaneously. So we're quite active there are multiple phases to each of these projects.
Thing that we always were concerned about in the past was we signed a contract and get a commitment and then it was sometimes talk to mobilize the customers. What we found for these two particular customers is that they are mobilized inactive and as fast as we can move and they can move we're making great progress so pretty dependable in terms of how we see our outlook in the business both for the first and.
Second quarter and of course, we're going after the next large companies to put things behind.
To put things behind us in our pipeline.
Okay. Thanks for that and my my seconds just on Genewiz.
Can you just talk about the opportunity you have with cross selling from the Srs platform into Genewiz.
Is that meaningful today or is it still fairly early stage.
Thanks, so much for taking the questions.
So David a couple of things it's meaningful from the standpoint of there's a lot of activity and we're beginning to we're beginning to generate business.
As a center.
Focus for the company. So we will talk in some more specifics next week at the analyst a as we prepared to get ourselves around answering that question, we see lower business levels right now, but a lot of business activity by the time, we exit 22, it'll be it'll be measurable then meaningful but already the engagements are strong it's a matter of <unk>.
The entire.
Commercial organization mobilized behind Dan getting customers used to it but a large number of our customers purchase multiple capabilities from us but.
You will hear next week, how we've unified the commercial organization to formalize that so it is not a collection of transactions.
Single transaction with multiple capabilities embedded so we'll give a little bit of color to that next week and we will start to report on the synergies that come between the Srs and.
And the genomic services business.
Great Thanks, and congrats on the quarter.
Thanks, David.
So again for questions. It's the one followed by four on your keypad, you'll hear a three tone prompt that acknowledges you request.
Next question is from Mike, Okay, with Keybanc capital markets. Please go ahead.
Hey, guys. Thanks for the time.
Linda just on the Guy, who I'm guessing you'll provide FY 22 here at the analysts they coming out.
Turning to one too midpoint implies about 14% <unk>.
Compared to the 33% you just came off can you kind of just talking to puts and takes their and then are you fully discounting those kobe related revenue share I think it was what about 10 million and <unk> last year.
So not totally discounting is what you're seeing.
Mike.
Is.
Almost a flat quarter quarter to quarter sequentially and Ah wrapped around on the rebound in queue for last year when we had.
I'm, sorry, Q1, and the December quarter. When you recall, we had this rebound from catch up on the genomics business, which really.
Accelerated quite a lot at that point now I'm not we're not taking that for granted.
Are we complacent with that but but the dynamics I'll add a little colors. We just spoke to the services business, having a little strength into the December quarter. Our products businesses is expecting just a little bit softer we had ah.
What I believe is a record growth quarter on our <unk>.
Store systems in total we had some remarkable placements of our cryo products and are.
Large system stores.
Being placed in the work completed on large projects and while it will continue to do well in the next quarter there'll be a touch softer and our consumables, we expect to be just a little bit softer to his people absorb what.
What they've taken and wait for the new calendar year budgets to take more so that's that's our expectation a little softer on the products a little stronger on services, so still expansion quarter to quarter as I just highlighted on both of US are us and even on the gene was business, but on the compare it's bringing us back down and.
I'd say this atmosphere of.
Around.
You can think of this is more in the high teens, but I.
I see or hear calculation on the 14, $14 15 percentage that midpoint.
Three.
Great and then Steve I think the number that stood out the most was the 79% reported growth in stores can you kind of unpacked out a little bit and you know is it specifically the cryo for.
<unk> therapy or are you starting to see customers.
Obviously, you're I think you're seeing customers by multiple units, but you're also seeing customers in terms of validation of it in the manufacturing line and being able to put it into cgmp setting are you seeing that starting to be more accepted an accelerated there.
We are already starting to see it on the we had a we had a <unk>.
Record quarter by far in the cryo space.
It was.
Biggest quarter by foreign shipments and in revenue.
Just locally here in Massachusetts, we shipped seven units for sale in gene therapy to a local company, we're starting to see those episodically, but they're beginning to fill it in so I think without question there were getting traction in that space and it's exciting time for us. So we're we're beginning to see.
People really understanding the need for automation here, especially handling those critical samples, it's cryogenic temperatures and the momentum is building.
Can't tell you that's going to that is going to sustain a quarters like that but we will see those coming more frequently than we do have.
Pretty high expectations for the business here beginning in.
Fiscal 22.
Great. Thanks for the time.
We have nothing for them from the phones I would like to turn it back to Lynn Robertson for closing Omer.
Alright, Thank you very much and for those who have tuned in with US. Obviously this was transformational year for us and certainly a quarter of significant change in the dynamics of our business. It set the stage for us into life Sciences launch and we look forward to telling you much more about that on.
Tuesday, and our Investor day, and with that we really appreciate your following us to your interest and.
Tuning in with us, but we will look forward to some more time with your next week. Thank you very much.
And that does conclude our call for today and we thank everyone for participating and you may now disconnect.
[music].